Literature DB >> 19387533

Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation.

Min-Jie Ju1, Shuang-Jian Qiu, Jia Fan, Jian Zhou, Qiang Gao, Ming-Yan Cai, Yi-Wei Li, Zhao-You Tang.   

Abstract

BACKGROUND: The ratio of serum gamma-glutamyl transferase (GGT) to alanine aminotransferase (ALT) is a parameter for assessing responses to antiviral therapies. The relationship between the prognosis of hepatitis B-associated hepatocellular carcinoma (HCC) and preoperative GGT/ALT is studied in hepatectomized Child-Pugh A patients.
METHODS: Two hundred and nineteen patients with hepatitis B virus-related HCC were included. Serum ALT and GGT levels were examined preoperatively and the GGT/ALT ratios were calculated. Their prognostic capabilities were evaluated by Cox-regression model.
RESULTS: As dichotomized variables, GGT and ALT were distributed unequally (P < 0.001). Most patients had high levels of GGT (n = 110) but low levels of ALT (n = 185). ALT displayed no relation to recurrence or survival, while GGT was independently associated with survival (P = 0.002). The GGT/ALT ratio could predict survival precisely either in a continuous or dichotomized fashion (P < 0.001 and 0.001, respectively), and also related to recurrence when dichotomized (P = 0.002). Additionally, high GGT/ALT ratio was associated with high early recurrence rates, more recurrence-related deaths and various aggressive tumor characteristics such as larger tumor size, vascular invasion, poor encapsulation and advanced BCLC stage. In further stratified analyses, this ratio could discriminate the outcomes of patients with high- or low-alpha-fetoprotein level.
CONCLUSIONS: The elevated GGT/ALT ratio was a promising predictor for poor prognosis of Child-Pugh A HCC patients after operation mainly through its tight relevance to the primary tumor burden.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387533     DOI: 10.1007/s00535-009-0050-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  36 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.

Authors:  G Tarantino; P Sorrentino; P Conca; A Perrella; P Ragucci; O Perrella
Journal:  Liver Int       Date:  2003-12       Impact factor: 5.828

Review 3.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

4.  Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy.

Authors:  Yue-Sun Cheung; Henry L Y Chan; John Wong; Kit-Fai Lee; Terence C W Poon; Nathalie Wong; Paul B S Lai
Journal:  Asian J Surg       Date:  2008-04       Impact factor: 2.767

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Ju-Bo Zhang; Peng-Yuan Zhuang; Hong-Guang Zhu; Wei Zhang; Yu-Quan Xiong; Wei-Zhong Wu; Lu Wang; Zhao-You Tang; Hui-Chuan Sun
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

8.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

9.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

10.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17
View more
  24 in total

1.  Ambient Ionization Mass Spectrometry Measurement of Aminotransferase Activity.

Authors:  Xin Yan; Xin Li; Chengsen Zhang; Yang Xu; R Graham Cooks
Journal:  J Am Soc Mass Spectrom       Date:  2017-01-31       Impact factor: 3.109

2.  Liver transplantation: a simple inflammation marker predicts liver cancer prognosis.

Authors:  Zhao-You Tang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-07-04       Impact factor: 46.802

Review 3.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.

Authors:  Hiromi Kan; Sho-ichi Yamagishi; Ayako Ojima; Kei Fukami; Seiji Ueda; Masayoshi Takeuchi; Hideyuki Hyogo; Hiroshi Aikata; Kazuaki Chayama
Journal:  J Clin Lab Anal       Date:  2014-09-23       Impact factor: 2.352

5.  Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma.

Authors:  Pinzhu Huang; Chunhong Liu; Binkui Li; Yun Zheng; Ruhai Zou; Jun Huang; Zemin Hu; Yunfei Yuan
Journal:  Mol Clin Oncol       Date:  2015-12-10

6.  Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.

Authors:  Wei Zhang; Gang Zhao; Kai Wei; Qingxiang Zhang; Weiwei Ma; Qiang Wu; Ti Zhang; Dalu Kong; Qiang Li; Tianqiang Song
Journal:  Med Oncol       Date:  2015-03-07       Impact factor: 3.064

7.  Risk factors for residual tumor after resection of hepatocellular carcinoma.

Authors:  Xiao-Hong Chen; Bo-Heng Zhang; Yin Xin; Zheng-Gang Ren; Jia Fan; Shuang-Jian Qiu; Jian Zhou
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

8.  Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the γ-Glutamyl Transpeptidase-to-Albumin Ratio.

Authors:  Shujie Pang; Yang Shi; Dapeng Xu; Hui Si-Ma; Ning Yang; Zhe Sun; Yiming Chen; Yingcheng Yang; Xijun Zhao
Journal:  J Gastrointest Surg       Date:  2022-08       Impact factor: 3.267

9.  Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes.

Authors:  Hiroki Nishikawa; Yukio Osaki; Eriko Iguchi; Haruhiko Takeda; Fumihiro Matsuda; Jun Nakajima; Azusa Sakamoto; Keiichi Hatamaru; Sumio Saito; Akihiro Nasu; Ryuichi Kita; Toru Kimura
Journal:  J Gastroenterol       Date:  2012-10-12       Impact factor: 7.527

10.  Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection.

Authors:  Xiaohong Chen; Boheng Zhang; Xin Yin; Zhenggang Ren; Shuangjian Qiu; Jian Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.